Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus.

Shashkova EV, May SM, Doronin K, Barry MA.

Mol Ther. 2009 Dec;17(12):2121-30. doi: 10.1038/mt.2009.217. Epub 2009 Sep 15.

2.

Systemic adenoviral gene delivery to orthotopic murine breast tumors with ablation of coagulation factors, thrombocytes and Kupffer cells.

Koski A, Rajecki M, Guse K, Kanerva A, Ristimäki A, Pesonen S, Escutenaire S, Hemminki A.

J Gene Med. 2009 Nov;11(11):966-77. doi: 10.1002/jgm.1373.

PMID:
19670332
3.

Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer.

Alba R, Bradshaw AC, Parker AL, Bhella D, Waddington SN, Nicklin SA, van Rooijen N, Custers J, Goudsmit J, Barouch DH, McVey JH, Baker AH.

Blood. 2009 Jul 30;114(5):965-71. doi: 10.1182/blood-2009-03-208835. Epub 2009 May 8.

4.

Redundant and synergistic mechanisms control the sequestration of blood-born adenovirus in the liver.

Di Paolo NC, van Rooijen N, Shayakhmetov DM.

Mol Ther. 2009 Apr;17(4):675-84. doi: 10.1038/mt.2008.307. Epub 2009 Feb 17.

5.

Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with oncolytic adenovirus.

Shashkova EV, Doronin K, Senac JS, Barry MA.

Cancer Res. 2008 Jul 15;68(14):5896-904. doi: 10.1158/0008-5472.CAN-08-0488.

6.

Substitution of hexon hypervariable region 5 of adenovirus serotype 5 abrogates blood factor binding and limits gene transfer to liver.

Vigant F, Descamps D, Jullienne B, Esselin S, Connault E, Opolon P, Tordjmann T, Vigne E, Perricaudet M, Benihoud K.

Mol Ther. 2008 Aug;16(8):1474-80. doi: 10.1038/mt.2008.132. Epub 2008 Jun 17.

7.

Development of an optimized conditionally replicative adenoviral agent for ovarian cancer.

Zhu ZB, Lu B, Park M, Makhija SK, Numnum TM, Kendrick JE, Wang M, Tsuruta Y, Fisher P, Alvarez RD, Zhou F, Siegal GP, Wu H, Curiel DT.

Int J Oncol. 2008 Jun;32(6):1179-88.

PMID:
18497979
8.

Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo.

Kalyuzhniy O, Di Paolo NC, Silvestry M, Hofherr SE, Barry MA, Stewart PL, Shayakhmetov DM.

Proc Natl Acad Sci U S A. 2008 Apr 8;105(14):5483-8. doi: 10.1073/pnas.0711757105. Epub 2008 Apr 7.

9.

Keeping adenovirus away from the liver.

Imperiale MJ.

Cell Host Microbe. 2008 Mar 13;3(3):119-20. doi: 10.1016/j.chom.2008.02.007.

10.

Adenovirus serotype 5 hexon mediates liver gene transfer.

Waddington SN, McVey JH, Bhella D, Parker AL, Barker K, Atoda H, Pink R, Buckley SM, Greig JA, Denby L, Custers J, Morita T, Francischetti IM, Monteiro RQ, Barouch DH, van Rooijen N, Napoli C, Havenga MJ, Nicklin SA, Baker AH.

Cell. 2008 Feb 8;132(3):397-409. doi: 10.1016/j.cell.2008.01.016.

11.

Gene therapy clinical trials worldwide to 2007--an update.

Edelstein ML, Abedi MR, Wixon J.

J Gene Med. 2007 Oct;9(10):833-42. Review.

PMID:
17721874
12.

Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes.

Parker AL, Waddington SN, Nicol CG, Shayakhmetov DM, Buckley SM, Denby L, Kemball-Cook G, Ni S, Lieber A, McVey JH, Nicklin SA, Baker AH.

Blood. 2006 Oct 15;108(8):2554-61. Epub 2006 Jun 20.

13.

Identification of sites in adenovirus hexon for foreign peptide incorporation.

Wu H, Han T, Belousova N, Krasnykh V, Kashentseva E, Dmitriev I, Kataram M, Mahasreshti PJ, Curiel DT.

J Virol. 2005 Mar;79(6):3382-90.

14.
15.

Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.

Sun J, Blaskovich MA, Jain RK, Delarue F, Paris D, Brem S, Wotoczek-Obadia M, Lin Q, Coppola D, Choi K, Mullan M, Hamilton AD, Sebti SM.

Cancer Res. 2004 May 15;64(10):3586-92.

16.

Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus.

Kanerva A, Zinn KR, Chaudhuri TR, Lam JT, Suzuki K, Uil TG, Hakkarainen T, Bauerschmitz GJ, Wang M, Liu B, Cao Z, Alvarez RD, Curiel DT, Hemminki A.

Mol Ther. 2003 Sep;8(3):449-58.

17.

Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon.

Wu H, Dmitriev I, Kashentseva E, Seki T, Wang M, Curiel DT.

J Virol. 2002 Dec;76(24):12775-82.

18.

Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells.

Kanerva A, Mikheeva GV, Krasnykh V, Coolidge CJ, Lam JT, Mahasreshti PJ, Barker SD, Straughn M, Barnes MN, Alvarez RD, Hemminki A, Curiel DT.

Clin Cancer Res. 2002 Jan;8(1):275-80.

Supplemental Content

Support Center